Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on qu...
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Background:
Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability versus dimethyl fumarate (DMF) with fewer days of Individual Gastrointestinal Symptom and Impact Scale (IGISIS) scores ⩾2, GI adverse events (AEs), and t...
Alternative Titles
Full title
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_7dcf8de81cf441938990675a654ee297
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7dcf8de81cf441938990675a654ee297
Other Identifiers
ISSN
1756-2864,1756-2856
E-ISSN
1756-2864
DOI
10.1177/1756286421993999
